About Genomind
Genomind is a company based in King Of Prussia (United States) founded in 2009.. Genomind has raised $64.43 million across 7 funding rounds from investors including SVB, HHS and Claritas Capital. Genomind operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter King Of Prussia, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genomind, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$64.43 M (USD)
in 7 rounds
-
Latest Funding Round
$399.59 K (USD), Grant
Sep 21, 2023
-
Investors
SVB
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Genomind
Genomind has successfully raised a total of $64.43M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $399.59 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $399,593
-
First Round
First Round
(09 Apr 2014)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Grant - Genomind | Valuation |
investors |
|
| Apr, 2021 | Amount | Series C - Genomind | Valuation |
investors |
|
| Jul, 2018 | Amount | Series C - Genomind | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genomind
Genomind has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, HHS and Claritas Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to early-stage real estate projects.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genomind
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genomind
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genomind Comparisons
Competitors of Genomind
Genomind operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genomind
Frequently Asked Questions about Genomind
When was Genomind founded?
Genomind was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Where is Genomind located?
Genomind is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Who is the current CEO of Genomind?
Bill Brown is the current CEO of Genomind.
Is Genomind a funded company?
Genomind is a funded company, having raised a total of $64.43M across 7 funding rounds to date. The company's 1st funding round was a Series C of $20.58M, raised on Apr 09, 2014.
What does Genomind do?
Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genominds PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.
Who are the top competitors of Genomind?
Genomind's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Who are Genomind's investors?
Genomind has 3 investors. Key investors include SVB, HHS, and Claritas Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.